Literature DB >> 2547486

The effects of drugs interacting with opioid receptors on the early ventricular arrhythmias arising from myocardial ischaemia.

R Sitsapesan1, J R Parratt.   

Abstract

1. The effects of a range of opioid receptor agonists and antagonists with differing opioid receptor selectivities on ischaemia-induced arrhythmias in anaesthetised rats was investigated. 2. Naloxone was antiarrhythmic only at doses expected to antagonise kappa- and delta-receptors in addition to mu-receptors. 3. The opioid receptor antagonist Mr 2266, which is twice as potent at kappa-receptors as at mu-receptors dose-dependently reduced the incidence and severity of the arrhythmias resulting from coronary artery occlusion. 4. The opioid receptor antagonist M 8008 (1 mg kg-1), which is twice as potent at delta-receptors as at mu-receptors but has very little affinity for the kappa-receptor, did not exhibit any beneficial antiarrhythmic properties. 5. MrZ 2593, a quarternary complex of naloxone which does not readily cross the blood brain barrier, was antiarrhythmic which implies that the antiarrhythmic actions of opioid receptor antagonists may be mediated via peripheral opioid receptors. 6. The agonists, diamorphine, [Leu] enkephalin and U-50,488H exhibited no significant arrhythmogenic effects under the present experimental conditions. 7. It is tentatively suggested that blockade of peripheral kappa-receptors during acute myocardial ischaemia may result in an antiarrhythmic effect.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547486      PMCID: PMC1854564          DOI: 10.1111/j.1476-5381.1989.tb12018.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Changes in cardiovascular sensitivity of alloxan-treated diabetic rats to arachidonic acid.

Authors:  A L Boura; W C Hodgson; R G King
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

2.  A kappa opioid effect: increased urination in the rat.

Authors:  J D Leander
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

3.  Multiple opioid receptor profile in vitro and activity in vivo of the potent opioid antagonist Win 44,441-3.

Authors:  S J Ward; A K Pierson; W F Michne
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

Review 4.  Classification of opioid receptors.

Authors:  S J Paterson; L E Robson; H W Kosterlitz
Journal:  Br Med Bull       Date:  1983-01       Impact factor: 4.291

5.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

6.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

7.  Naloxone inhibits early arrhythmias resulting from acute coronary ligation.

Authors:  O Fagbemi; I Leprán; J R Parratt; L Szekeres
Journal:  Br J Pharmacol       Date:  1982-08       Impact factor: 8.739

8.  Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity.

Authors:  G Bianchi; R Fiocchi; A Tavani; L Manara
Journal:  Life Sci       Date:  1982-05-31       Impact factor: 5.037

9.  Coronary artery ligation in anesthetized rats as a method for the production of experimental dysrhythmias and for the determination of infarct size.

Authors:  C Clark; M I Foreman; K A Kane; F M McDonald; J R Parratt
Journal:  J Pharmacol Methods       Date:  1980-06

10.  Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia.

Authors:  O Fagbemi; K A Kane; I Leprán; J R Parratt; L Szekeres
Journal:  Br J Pharmacol       Date:  1983-03       Impact factor: 8.739

View more
  6 in total

1.  Electrophysiological and antiarrhythmic actions of the kappa agonist PD 129290, and its R,R (+)-enantiomer, PD 129289.

Authors:  M K Pugsley; D A Saint; M P Penz; M J Walker
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

2.  Failure to reproduce the in vitro cardiac electrophysiological effects of naloxone in humans.

Authors:  K G Oldroyd; A C Rankin; C E Gray; K Harvey; W Borland; A P Rae; S M Cobbe
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

3.  The antiarrhythmic and cardiac electrophysiological effects of buprenorphine.

Authors:  G Boachie-Ansah; R Sitsapesan; K A Kane; J R Parratt
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

4.  Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.

Authors:  M K Pugsley; W P Penz; M J Walker; T M Wong
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

5.  Beta endorphin release in patients after spontaneous and provoked acute myocardial ischaemia.

Authors:  K G Oldroyd; K Harvey; C E Gray; G H Beastall; S M Cobbe
Journal:  Br Heart J       Date:  1992-03

Review 6.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.